Patent US3977015A successfully refreshed from Google Patents.
Patent US2363323A successfully refreshed from Google Patents.
Patent US4987139A successfully refreshed from Google Patents.
US4987139A
Expired / Lapsed
US
⏱️ 0.0 years remaining
FK-520 microbial transformation product
Assignee: Merck and Co Inc
•
Filing: 1989-05-05
•
Granted: 1991-01-22
•
Expires: 2009-05-05
Abstract
Abstract Described is a new immunosuppressant, L-687,795, a C-13, C-15, C-31 trisdemethylated, ring rearranged derivative of L-683,590, produced under fermentation conditions utilizing the microorganism, Actinoplanacete sp. (Merck Culture Collection MA 6559) ATCC No. 53771. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.
Inventors
- 👤 Shieh-Shung T. Chen
- 👤 Linda S. Wicker
- 👤 Byron H. Arison
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 06:24
CPC Classifications
C; C12; C12P; C12P17/00; C12P17/18; C12P17/188
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
39 words
An immunosuppressant, designated as L-687,795, which exhibits: positive inhibition of T-cell activation by the T-cell proliferation assay, a proton nuclear magnetic spectrogram as depicted in FIG. 1, and a molecular weight of 749 as determined by FAB mass spectroscopy.
Claim 2
Dependent Claim
39 words
An immunosuppressant, designated as L-687,795, which exhibits: positive inhibition of T-cell activation by the T-cell proliferation assay, a proton nuclear magnetic spectrogram as depicted in FIG. 1, and a molecular weight of 749 as determined by FAB mass spectroscopy.
Claim 3
Dependent Claim
13 words
An immunosuppresant, L-687,795, which has a molecular structure as depicted in FIG. 1.
Claim 4
Dependent Claim
13 words
An immunosuppresant, L-687,795, which has a molecular structure as depicted in FIG. 1.
Claim 5
Dependent Claim
21 words
A pharmaceutical composition containing a therapeutically effective amount of L-687,795 in combination with a pharmaceutically acceptable, substantially non-toxic carrier or excipient.
Claim 6
Dependent Claim
21 words
A pharmaceutical composition containing a therapeutically effective amount of L-687,795 in combination with a pharmaceutically acceptable, substantially non-toxic carrier or excipient.
Claim 7
Independent Claim
32 words
A method of use for treating a human host to prevent transplantation rejection, or for treating autoimmune disease or infectious disease comprising administering to said host a therapeutically effective amount of L-687,795.
Claim 8
Independent Claim
32 words
A method of use for treating a human host to prevent transplantation rejection, or for treating autoimmune disease or infectious disease comprising administering to said host a therapeutically effective amount of L-687,795.
References Cited (Backward Citations)
US3244592A
Cited
EP0184162A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-01-21 | 1994-07-23 | 1995-01-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-01-21 | 1998-07-23 | 1999-01-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-01-21 | 2002-07-23 | 2003-01-22 | $7700.00 | Window Closed / Lapsed |